---

HEMATOLOGY - COMPREHENSIVE ANSWERS

---

Q1. Hemorrhagic Disorders & Hemophilia

Definition of Hemorrhagic Disorders

Classification of Hemorrhagic Disorders

1. Vascular disorders - Hereditary hemorrhagic telangiectasia, scurvy, Henoch-Schonlein purpura
2. Platelet disorders - Thrombocytopenia, thrombocytopathy (qualitative defects)
3. Coagulation factor deficiencies - Hemophilia A & B, von Willebrand disease, DIC, liver disease

---

HEMOPHILIA

• Genetics: X-linked recessive - carried on the X chromosome, almost exclusively affects males (XY)
• Inheritance: Female carriers (X^H X) transmit to 50% of sons (affected) and 50% of daughters (carriers)
• Molecular basis: Deletions, inversions, point mutations in the F8 or F9 gene on the X chromosome
• Approximately one-third of cases arise from new mutations (no family history)
• Rarely, females can be affected via Turner syndrome (45,X), extreme lyonization, or if homozygous

• The extrinsic pathway (tissue factor/factor VIIa) can generate thrombin initially, producing a primary platelet plug normally
• However, sustained thrombin generation via the intrinsic amplification loop is severely impaired
• Clots form slowly, break down prematurely, and fail to achieve adequate hemostasis

• Hemarthroses (hallmark): blood in joint spaces - knees most commonly, followed by elbows, ankles, hips, shoulders
• Chronic hemarthrosis leads to: synovial inflammation, cartilage destruction, joint fibrosis, epiphyseal overgrowth, limb length discrepancy, generalized osteopenia
• Intramuscular hematomas: particularly iliopsoas (can compress femoral nerve)
• Pseudotumors: encapsulated blood cysts from repeated intramuscular bleeding
• Squaring of the patella and condyles on imaging (chronic hemophilic arthropathy)

• Spontaneous hemarthrosis - painful, warm, swollen joint with restricted range of motion
• Deep soft tissue bleeding (vs. petechiae in platelet disorders)
• Prolonged bleeding after dental extraction, surgery, or circumcision
• Retroperitoneal and intracranial hemorrhage in severe cases
• Hematuria
• Primary platelet plug is normal - superficial cuts may stop bleeding initially

• The aPTT tests the intrinsic and common pathways; PT tests the extrinsic and common pathway
• In hemophilia, only the intrinsic pathway is deficient, so PT is normal and aPTT is prolonged
• Mixing study: patient plasma + normal plasma normalizes aPTT (factor deficiency, not inhibitor)
• Factor-specific assay confirms diagnosis and quantifies severity
• von Willebrand factor antigen and activity should also be measured to exclude vWD (where factor VIII may be low)

---

Q2. Laboratory Diagnosis in a Case of Bleeding Gums

Causes to Consider

1. Local/dental: Gingivitis, periodontitis, calculus
2. Platelet disorders: Thrombocytopenia (ITP, aplastic anemia, leukemia), thrombocytopathy (aspirin, uremia)
3. Coagulation defects: Liver disease, hemophilia, DIC
4. Vascular disorders: Scurvy (vitamin C deficiency), hereditary hemorrhagic telangiectasia
5. Drugs: Anticoagulants (warfarin, heparin), antiplatelets

Laboratory Evaluation - Step-by-Step

• vWF antigen (quantitative)
• vWF ristocetin cofactor activity (functional)
• Factor VIII coagulant activity
• vWF multimer analysis

---

Q3. Thrombocytopenia - Classification & Primary ITP

Classification of Thrombocytopenia

• Aplastic anemia (bone marrow failure)
• Leukemia / myelodysplastic syndrome (marrow infiltration)
• Megaloblastic anemia (B12/folate deficiency)
• Chemotherapy, radiation
• Viral infections (HIV, CMV, EBV, hepatitis)
• Inherited: Fanconi anemia, amegakaryocytic thrombocytopenia

• Immune-mediated:
  • Primary immune thrombocytopenia (ITP)
  • Secondary ITP (SLE, HIV, HCV, medications)
  • Drug-induced thrombocytopenia (DITP: heparin/HIT, quinine)
  • Post-transfusion purpura
• Non-immune:
  • TTP (thrombotic thrombocytopenic purpura)
  • HUS (hemolytic uremic syndrome)
  • DIC
  • HELLP syndrome

• Hypersplenism (portal hypertension, storage diseases)

• Massive transfusion

---

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

1. Autoantibody production: Autoreactive B cells produce IgG autoantibodies (predominantly IgG1 and IgG3) directed against platelet surface glycoproteins, mainly GPIIb/IIIa (fibrinogen receptor, integrin αIIbβ3) and GPIb/IX (vWF receptor)
2. Splenic destruction: Antibody-coated platelets are recognized by Fc receptors on splenic macrophages and destroyed by phagocytosis (extravascular destruction) - the spleen is the primary site
3. Impaired megakaryopoiesis: Anti-GPIIb/IIIa antibodies can bind to megakaryocytes, impairing platelet production and causing premature fragmentation - hence thrombopoietin levels may be lower than expected
4. T-cell dysregulation: Loss of regulatory T cells (Treg), skewing toward Th1/Th17 responses, cytotoxic T-cell-mediated platelet destruction
5. Liver: Secondary site of platelet destruction (Kupffer cells)

• Acute ITP (children): Abrupt onset after viral illness (2-3 weeks prior), predominantly ages 2-6 years, platelet count often <20,000/µL, >90% spontaneous remission within weeks-months
• Chronic ITP (adults): Insidious onset, female predominance (3:1), platelet count 30,000-100,000/µL, mucocutaneous bleeding (petechiae, purpura, ecchymoses, gum bleeding, menorrhagia)
• Signs: petechiae (especially in dependent areas), purpura, mucosal bleeding; splenomegaly is usually absent (distinguishes from secondary causes)
• Life-threatening: intracranial hemorrhage at platelet counts <10,000/µL

---

Q4. Laboratory Evaluation of Hemoglobinopathies

Laboratory Approach

• Microcytic hypochromic anemia: thalassemia, HbE, HbC trait
• Normocytic or macrocytic anemia with evidence of hemolysis: sickle cell disease
• Mentzer index (MCV/RBC): <13 suggests thalassemia; >13 suggests iron deficiency
• Target cells (codocytes): prominent in HbC disease, thalassemia, HbSC
• Sickle cells: HbSS, HbSC
• Nucleated RBCs, polychromasia: hemolysis or extramedullary hematopoiesis

• Sickle cell disease: sickle cells, target cells, Howell-Jolly bodies (asplenia), polychromasia
• Thalassemia major: hypochromic microcytic, target cells, nucleated RBCs, poikilocytosis, basophilic stippling
• HbC: abundant target cells, intracellular HbC crystals ("bar of gold")
• HbH disease (alpha-thalassemia): inclusion bodies with brilliant cresyl blue stain

• Performed on cellulose acetate (alkaline pH 8.4) and citrate agar (acid pH 6.0)
• At alkaline pH: HbA (fastest), then HbF, HbS, HbC (slowest)
• HbS and HbD co-migrate at alkaline pH but separate at acid pH (important for HbS confirmation)
• Detects: HbS, HbC, HbE, HbD, HbH, elevated HbF, elevated HbA2

• Ion-exchange chromatography separates hemoglobin variants by retention time
• Quantifies HbA, HbA2, HbF, HbS, HbC, and other variants
• HbA2 >3.5% + microcytosis = beta-thalassemia trait
• HbF elevated in HPFH, sickle cell disease, beta-thalassemia
• Can detect variants missed by electrophoresis

• PCR-based genotyping for known mutations (e.g., HbS: Glu6Val, beta-zero/beta-plus mutations)
• Gap-PCR for alpha-globin deletions (--SEA, -alpha3.7, -alpha4.2)
• Multiplex MLPA or NGS for comprehensive hemoglobin gene panel
• Prenatal diagnosis: chorionic villus sampling (CVS) at 10-12 weeks

---

Q5. Hemolytic Anemias - Classification & Immune Hemolytic Anemia

Definition

Classification

1. Membrane defects: Hereditary spherocytosis, hereditary elliptocytosis
2. Enzyme defects: G6PD deficiency, pyruvate kinase deficiency
3. Hemoglobinopathies: Sickle cell disease, thalassemia, HbC

1. Immune: Autoimmune hemolytic anemia (AIHA), alloimmune (transfusion reactions, HDN)
2. Microangiopathic: TTP, HUS, DIC, prosthetic heart valves
3. Infectious: Malaria (falciparum), clostridial sepsis, Bartonella
4. Chemical/toxic: Dapsone, lead poisoning
5. Hypersplenism

---

IMMUNE HEMOLYTIC ANEMIA (IHA / AIHA)

1. Drug adsorption (hapten) mechanism: Drug (e.g., penicillin) binds firmly to RBC membrane; antibody to drug-RBC complex causes hemolysis
2. Immune complex (innocent bystander): Drug-antibody complexes adsorb onto RBCs and activate complement (e.g., quinine)
3. Autoantibody induction: Drug induces true autoantibodies to RBC (e.g., methyldopa, fludarabine)

• ANA, anti-dsDNA: exclude SLE
• SPEP/immunofixation: lymphoproliferative disease
• HIV, EBV, Mycoplasma serology: secondary causes
• Drug history review

• Osmotic fragility (hereditary spherocytosis if AIHA excluded by negative DAT)
• G6PD assay (after acute hemolysis resolves, as reticulocytes have higher G6PD)
• Hb electrophoresis / HPLC (hemoglobinopathies)
• ADAMTS13 level (TTP if schistocytes present)
• Flow cytometry for CD55/CD59 (PNH - complement-mediated intravascular hemolysis)

---

Q6. Erythroblastosis Fetalis (Hemolytic Disease of the Newborn - HDN)

Definition

Etiology and Pathogenesis

1. Sensitization: An Rh-negative (Rh D-negative) mother carries an Rh-positive fetus. At delivery (or during abortions/invasive procedures), fetal Rh-positive RBCs enter the maternal circulation (fetomaternal hemorrhage), stimulating maternal IgM (primary response, does not cross placenta)
2. Re-exposure: In a subsequent Rh-positive pregnancy, the mother rapidly produces IgG anti-D antibodies (anamnestic/secondary response)
3. Transplacental passage: IgG (unlike IgM) freely crosses the placenta via FcRn receptors and binds to fetal RBCs
4. Fetal hemolysis: Antibody-coated fetal RBCs are destroyed by macrophages (splenic and hepatic), causing hemolytic anemia
5. Compensation: Compensatory erythropoiesis - first in bone marrow, then extramedullary (liver, spleen causing hepatosplenomegaly), releasing immature nucleated RBCs (erythroblasts) - giving the disease its name

Consequences

• Fetal anemia: Compensated by extramedullary hematopoiesis
• Hydrops fetalis: Severe anemia causes high-output cardiac failure, generalized edema, ascites, pleural effusions, hypoproteinemia
• Hyperbilirubinemia after birth: Placenta removes bilirubin in utero; after delivery, the neonate's immature liver cannot conjugate the bilirubin load from ongoing hemolysis
• Kernicterus: Unconjugated (lipophilic) bilirubin crosses the blood-brain barrier, depositing in basal ganglia, hippocampus, and other areas, causing permanent neurological damage, choreoathetosis, sensorineural deafness, and intellectual disability

Laboratory Diagnosis

Spectrophotometric Analysis of Amniotic Fluid (Liley Test)

• Zone I: mild/no disease
• Zone II: moderate disease - requires close monitoring
• Zone III: severe disease - immediate delivery or intrauterine transfusion

Treatment

• Phototherapy (converts bilirubin to water-soluble isomers)
• Exchange transfusion (removes antibody-coated RBCs and reduces bilirubin)
• Intrauterine transfusion for severe fetal anemia
• Prevention: Anti-D immunoglobulin (Rh-Ig, RhoGAM) given to Rh-negative mothers at 28-30 weeks gestation and within 72 hours of delivery of an Rh-positive baby - this passive anti-D clears fetal RBCs before maternal sensitization can occur

---

Q7. Polycythemia - Classification and Discussion

Definition

Classification

POLYCYTHEMIA
│
├── RELATIVE (Spurious/Apparent)
│   ├── Dehydration (vomiting, diarrhea, burns)
│   ├── Spurious (Gaisböck syndrome): Normal RCM, reduced plasma volume
│   └── Stress polycythemia: obesity, hypertension, smoking
│
└── ABSOLUTE (True - increased total red cell mass)
    │
    ├── PRIMARY (autonomous erythroid proliferation, EPO low/normal)
    │   ├── Polycythemia Vera (PV) - JAK2 V617F mutation
    │   └── Inherited (mutated EPO receptor - rare)
    │
    └── SECONDARY (EPO-driven)
        ├── Appropriate (physiologic hypoxia → ↑EPO)
        │   ├── High altitude
        │   ├── Chronic lung disease (COPD)
        │   ├── Cyanotic congenital heart disease
        │   ├── Carboxyhemoglobinemia (smoking)
        │   ├── High O2-affinity hemoglobins
        │   └── Methemoglobinemia
        │
        └── Inappropriate (non-hypoxic EPO excess)
            ├── EPO-secreting tumors: renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma, Wilms tumor
            ├── Polycystic kidneys, renal artery stenosis
            ├── Post-renal transplant
            └── Exogenous EPO ("blood doping")

Polycythemia Vera (PV) - Primary

1. Hb >16.5 g/dL (men) or >16.0 g/dL (women) OR elevated RCM
2. Hypercellular BM with trilineage hyperplasia and pleomorphic megakaryocytes
3. JAK2 V617F or JAK2 exon 12 mutation

• Subnormal serum EPO level

• Primary (PV): Low EPO, JAK2 positive, panmyelosis
• Secondary: High EPO, JAK2 negative, erythroid hyperplasia only

---

Q8. Cytogenetics in Hematologic Malignancies

Why Cytogenetics Matters

• Diagnostic markers (WHO classification often requires cytogenetics)
• Prognostic indicators (favorable vs. unfavorable)
• Therapeutic targets (BCR-ABL → imatinib)
• Monitoring tool (minimal residual disease)

Methods

1. Conventional karyotype (G-banding): 20-25 metaphase cells analyzed; detects translocations, deletions, inversions at band resolution (~10 Mb)
2. Fluorescence in situ hybridization (FISH): Labeled DNA probes hybridize to specific chromosomal loci; detects known abnormalities in both dividing and non-dividing cells; useful for t(9;22), 17p deletion
3. RT-PCR: Detects specific fusion transcripts (BCR-ABL1, PML-RARA) at high sensitivity; used for diagnosis and MRD monitoring
4. Microarray (SNP array/CGH): Detects copy number variations, loss of heterozygosity at high resolution
5. Next-generation sequencing (NGS): Comprehensive mutation profiling (JAK2, NPM1, FLT3, IDH1/2, TP53, etc.)

Key Cytogenetic Abnormalities by Disease

• t(9;22)(q34;q11) - Philadelphia chromosome in virtually 100% of cases
• Creates BCR-ABL1 fusion gene encoding a constitutively active 210-kDa tyrosine kinase (p210)
• Activates Ras, STAT5, PI3K/Akt pathways promoting proliferation and inhibiting apoptosis
• BCR-ABL1 kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) are the treatment
• Loss of Philadelphia chromosome is the goal of therapy (major cytogenetic response)
• Additional cytogenetic changes (trisomy 8, isochromosome 17q, double Ph) = blast crisis

• MDS: del(5q), -7, del(7q), del(20q), -17, complex karyotype
• del(5q) MDS: isolated del(5q) = favorable, lenalidomide-responsive
• Myeloproliferative neoplasms: JAK2 V617F, CALR, MPL mutations (molecular, not cytogenetic)

---

Q9. Bone Marrow Failure Syndrome

Definition

Classification

1. Aplastic anemia (most common acquired BMFS)
   • Severe aplastic anemia (SAA): ANC <500/µL, platelets <20,000/µL, reticulocytes <1%
   • Moderate aplastic anemia (MAA)
   • Causes: idiopathic (majority - immune-mediated T-cell destruction), drugs (chloramphenicol, NSAIDs, sulfonamides, gold), radiation, viruses (EBV, CMV, HIV, hepatitis), PNH, pregnancy
2. Pure red cell aplasia (PRCA)
   • Selective absence of erythroid precursors
   • Causes: parvovirus B19 (aplastic crisis in chronic hemolysis), thymoma, CLL, drugs (EPO antibodies)
3. Amegakaryocytic thrombocytopenia
4. Myelophthisis - marrow replacement by fibrosis, metastatic tumor, granulomas

1. Fanconi anemia - autosomal recessive; defects in DNA repair (FANC genes); pancytopenia, skeletal anomalies, café-au-lait spots, increased cancer risk (AML, squamous cell carcinoma)
2. Dyskeratosis congenita - telomerase gene mutations (TERT, TERC, DKC1); skin pigmentation, nail dystrophy, oral leukoplakia
3. Shwachman-Diamond syndrome - SBDS gene mutation; neutropenia + exocrine pancreatic insufficiency
4. Diamond-Blackfan anemia - pure red cell aplasia; ribosomal protein mutations; congenital anomalies
5. Severe congenital neutropenia (Kostmann) - ELANE mutation; severe neutropenia from birth

Pathogenesis of Aplastic Anemia (Immune-mediated)

1. An initial trigger (virus, drug, or occult PNH clone) exposes HSC antigens
2. Oligoclonal expansion of CD8+ cytotoxic T cells (Th1-polarized)
3. Production of IFN-γ and TNF-α by activated T cells → induce Fas-FasL-mediated apoptosis of HSCs and inhibit hematopoietic growth
4. Regulatory T cell (Treg) deficiency allows unchecked immune activation
5. Reduced telomere length in HSCs (some cases have germline telomerase mutations)
6. Result: progressive depletion of all HSC lines → pancytopenia

Laboratory Diagnosis

Diagnosis of Severe Aplastic Anemia (Camitta Criteria)

• Neutrophils <500/µL (very severe: <200/µL)
• Platelets <20,000/µL
• Reticulocytes <1% (or <60,000/µL corrected)

Treatment

• Immunosuppression: anti-thymocyte globulin (ATG) + cyclosporine + eltrombopag
• Allogeneic stem cell transplantation (curative - first line in young patients with matched sibling donor)
• Supportive: RBC/platelet transfusions, G-CSF, antimicrobials

---

Q10. Pancytopenia - Pathogenesis & Diagnostic Approach

Definition

• Red blood cells (anemia: Hb <13 g/dL in men, <12 g/dL in women)
• White blood cells (leukopenia: WBC <4,000/µL; neutropenia: ANC <1,500/µL)
• Platelets (thrombocytopenia: <150,000/µL)

Classification / Causes

• Paroxysmal nocturnal hemoglobinuria (PNH): hemolysis + marrow aplasia

Pathogenesis (Special Emphasis)

• Deficiency of vitamin B12 or folate → impaired thymidylate synthesis → defective DNA replication
• "Maturation arrest": nuclear development lags behind cytoplasmic development (nucleocytoplasmic dissociation)
• Ineffective hematopoiesis: megaloblasts are destroyed in marrow (intramedullary hemolysis) before reaching circulation
• All cell lines affected: macro-ovalocytes, hypersegmented neutrophils, giant platelets, hypercellular marrow despite pancytopenia

• Clonal mutations in hematopoietic stem cells (splicing factors: SF3B1, SRSF2; epigenetic regulators: TET2, DNMT3A, ASXL1; transcription factors: RUNX1)
• Dysplastic (abnormal) cell morphology but ineffective hematopoiesis - cells fail to mature or undergo apoptosis in the marrow
• Peripheral blood pancytopenia with hypercellular or normocellular marrow (ineffective = production present but output absent)

• Marrow space replaced by tumor, fibrosis, or granulomas
• Leukoerythroblastic reaction: release of immature precursors (myelocytes, metamyelocytes, nucleated RBCs) into circulation because normal marrow architecture is disrupted
• Teardrop-shaped RBCs (dacryocytes): hallmark of myelofibrosis

• Enlarged spleen traps and destroys RBCs, WBCs, and platelets
• Marrow is hyperplastic (compensatory) - distinguishes from aplastic anemia
• Pancytopenia is modest (rarely severe)

• Immune-mediated: autoantibodies against RBCs (Coombs positive), platelets, and neutrophils
• Plus bone marrow suppression by inflammatory cytokines

Diagnostic Approach

• Drug/toxin/radiation history (aplastic, MDS)
• Family history (Fanconi, dyskeratosis congenita)
• Duration and symptoms: fatigue, infections, bleeding
• B-symptoms (fever, weight loss, night sweats): lymphoma, TB
• Travel history: Leishmaniasis

• CD59 (protectin) and CD55 (DAF) expression on RBCs and granulocytes
• Absent in PNH clones (PIGA gene mutation)
• PNH clone detected by flow cytometry in ~50% of aplastic anemia; may coexist

---

---

HEMATOLOGY - COMPREHENSIVE ANSWERS (SET 2)

---

Q1. Megaloblastic Anemia - Classification & Laboratory Diagnosis

Definition

Pathogenesis

Classification (Causes of Megaloblastic Anemia)

• Chemotherapy drugs inhibiting DNA synthesis (hydroxyurea, cytarabine, 6-mercaptopurine)
• Acute megaloblastic anemia (nitrous oxide - oxidizes B12 irreversibly)
• Congenital enzyme defects (orotic aciduria)
• Thiamine-responsive megaloblastic anemia (rare)

---

Laboratory Diagnosis

• Hb: low (often 7-8 g/dL, can be very low)
• MCV: markedly elevated (>100 fL, often 110-140 fL) - macrocytic anemia
• RDW: elevated (anisocytosis)
• WBC: low-normal (leukopenia)
• Platelets: low-normal (thrombocytopenia)
• Pancytopenia in severe cases (all cell lines affected due to global DNA synthesis impairment)

• Macro-ovalocytes (oval macrocytes) - hallmark; cells larger than normal, oval in shape, without central pallor
• Hypersegmented neutrophils - 5 or more lobes in a single neutrophil (1+ cells with ≥5 lobes, OR any cell with 6 lobes); earliest and most specific finding
• Anisocytosis, poikilocytosis
• Giant band neutrophils
• Normal MCHC (not truly hyperchromic despite appearing so)

• Methylmalonic acid is the most specific test to confirm functional B12 deficiency (elevated when B12 is metabolically deficient, even with borderline serum B12)
• RBC folate is more reliable than serum folate (less affected by recent dietary intake)
• Serum homocysteine is elevated in both deficiencies but is non-specific

• Elevated serum LDH (markedly, from intramedullary destruction)
• Elevated indirect bilirubin (breakdown of megaloblasts within marrow)
• Decreased haptoglobin
• Elevated serum iron and transferrin saturation

B12 or Folate deficiency
↓
↓ Thymidylate synthesis → defective DNA replication
↓
Megaloblasts in marrow → intramedullary hemolysis
↓                           ↓
Macro-ovalocytes in blood    Elevated LDH, indirect bilirubin
↓
Hypersegmented neutrophils, giant metamyelocytes, pancytopenia

---

Q2. Beta-Thalassemia - Molecular Pathogenesis & Laboratory Diagnosis

Overview

Molecular Genetics

• β⁰: No beta-globin synthesis (severe mutations)
• β⁺: Reduced beta-globin synthesis (mild to moderate mutations)
• β++: Mildly reduced (silent alleles)

Pathogenesis of Beta-Thalassemia Major (β⁰/β⁰ or β⁰/β⁺)

1. Deficient or absent beta chains → excess free alpha chains accumulate
2. Free alpha chains are unstable and precipitate within red cell precursors (inclusions/Heinz bodies) → membrane damage → premature destruction of erythroid precursors in the marrow = ineffective erythropoiesis (most important mechanism)
3. Red cells that do reach circulation are hypochromic, microcytic, fragile, and are removed by splenic macrophages = hemolysis
4. Profound anemia → massive erythropoietic drive → extramedullary hematopoiesis in liver, spleen, and bones
5. Expansion of erythroid marrow → "hair-on-end" skull X-ray appearance, facial deformities (chipmunk face), osteoporosis
6. Ineffective erythropoiesis increases iron absorption (via hepcidin suppression) and transfusions add more iron → iron overload → hemochromatosis affecting heart, liver, endocrine glands

• HbF (α2γ2) increases because gamma chain production is upregulated to compensate - cells with more HbF have less alpha chain precipitation and survive better
• HbA2 (α2δ2) mildly increases due to relative delta chain production

Clinical Variants

Laboratory Diagnosis

• HbA2 >3.5% is the diagnostic hallmark of beta-thalassemia trait
• In iron deficiency coexisting with beta-thal trait, HbA2 may be falsely normal (iron corrects before re-testing)

• Decreased osmotic fragility (resistance to lysis in hypotonic saline) because of target cells with excess membrane - opposite to hereditary spherocytosis

• PCR-based allele-specific oligonucleotide (ASO) hybridization for known mutations
• ARMS-PCR (amplification refractory mutation system) - detects specific point mutations
• MLPA or sequencing for unusual cases
• Gap-PCR: not applicable for beta-thalassemia (point mutations, not deletions - except for the rare deletional forms)
• Prenatal diagnosis: chorionic villus sampling (CVS) at 10-12 weeks, or amniocentesis at 15-20 weeks

• Erythroid hyperplasia (M:E ratio reversed, e.g., 1:4 instead of 3:1)
• Erythroid precursors with alpha chain inclusions (crystal violet stain)
• Increased iron stores

• Skull X-ray: "hair-on-end" appearance (perpendicular bone spicules from marrow expansion)
• Facial bones: expansion causes maxillary hypertrophy → "chipmunk facies"
• Osteoporosis on bone survey

---

Q3. Disorders of Iron Metabolism

Normal Iron Metabolism

• Hemoglobin: 65% (~2100 mg men, ~1750 mg women)
• Myoglobin: ~300 mg
• Enzymes (catalase, cytochromes): ~50 mg
• Storage (ferritin + hemosiderin in liver, spleen, bone marrow macrophages): ~1000 mg men, ~400 mg women

• Ferritin: Water-soluble protein-iron complex; mobile storage; serum ferritin reflects body stores (~1 μg/L = 8 mg storage iron)
• Hemosiderin: Insoluble aggregate of ferritin in lysosomes; stains Prussian blue (potassium ferrocyanide); predominates in iron overload

• Ferric (Fe³⁺) iron is reduced to ferrous (Fe²⁺) by duodenal cytochrome b reductase (DcytB); absorbed by DMT-1 transporter
• Inside enterocyte: stored as ferritin or exported via ferroportin (FPN1) at the basolateral surface
• Hepcidin (hepatic peptide) is the master regulator: binds ferroportin → internalization/degradation → blocks iron export from enterocytes and macrophages
• Elevated iron/inflammation → elevated hepcidin → decreased iron absorption
• Iron deficiency/increased erythropoiesis → suppressed hepcidin → increased absorption

---

Classification of Iron Metabolism Disorders

---

I. IRON DEFICIENCY ANEMIA (IDA)

1. Chronic blood loss (most important in adults): GI bleeding (peptic ulcer, carcinoma, hookworm - most important worldwide), menorrhagia
2. Inadequate dietary intake: Infants on breast milk alone, toddlers, strict vegetarians, elderly with poor diet
3. Increased demands: Pregnancy, infancy, adolescent growth spurt
4. Impaired absorption: Celiac disease, post-gastrectomy, H. pylori gastritis (impairs iron reduction)

• Small, pale RBCs (hypochromic microcytic) with increased central pallor (>1/3 diameter)
• Target cells, pencil cells (elongated hypochromic forms)
• Poikilocytosis
• Bone marrow: reduced/absent iron stores (Prussian blue stain); normoblastic hyperplasia; nuclear:cytoplasmic asynchrony (nuclear maturation normal; cytoplasmic hemoglobin reduced)
• Systemic effects of chronic IDA: koilonychia (spoon nails), glossitis, angular cheilosis, Plummer-Vinson syndrome (esophageal web + dysphagia)

---

II. ANEMIA OF CHRONIC INFLAMMATION (ACD)

---

III. IRON OVERLOAD (HEMOCHROMATOSIS)

• HFE gene mutations on chromosome 6p (C282Y - most common in Northern Europeans; H63D); loss of normal hepcidin regulation → unregulated iron absorption
• Autosomal recessive; iron accumulates progressively in liver (cirrhosis), pancreas (diabetes), heart (cardiomyopathy), skin (bronze pigmentation), joints (arthropathy), pituitary (hypogonadism)

• Chronic transfusion therapy (thalassemia, sickle cell disease)
• Dysmetabolic syndrome
• Dietary iron overload (African iron overload)

• Elevated serum iron; very elevated transferrin saturation (>45%, often >80%)
• Elevated serum ferritin (>1000 μg/L, often >5000 μg/L)
• Liver biopsy: Prussian blue stain shows massive iron deposits in hepatocytes
• MRI liver: reduced signal on T2 (iron is paramagnetic)
• HFE gene testing: C282Y homozygous confirms hereditary hemochromatosis

---

IV. SIDEROBLASTIC ANEMIA

---

Q4. Red Cell Indices

The Four Major Indices

• Definition: Average volume of a single red blood cell
• Formula: MCV = (Hematocrit × 10) / RBC count (in millions/µL)
• In automated analyzers: MCV is a direct primary measurement from cell counter; Hct is derived (Hct = MCV × RBC)
• Normal: 80-96 fL (adults)
• Newborn: 104-118 fL (physiologically macrocytic)
• Clinical use:
  • Microcytic (<80 fL): IDA, thalassemia, sideroblastic anemia, ACD (sometimes)
  • Normocytic (80-100 fL): acute blood loss, hemolysis, aplastic anemia, ACD, renal disease
  • Macrocytic (>100 fL): megaloblastic anemia, liver disease, hypothyroidism, drugs, reticulocytosis

• Definition: Average mass of hemoglobin in a single RBC
• Formula: MCH (pg) = Hb (g/dL) / RBC count (in millions/µL) × 10
  • If Hb = 15 g/dL and RBC = 5 × 10¹²/L → MCH = 150 / (5 × 10¹²) = 30 pg
• 1 pg = 10⁻¹² g
• Normal: 27-33 pg
• In automated analyzers: MCH = Hb/RBC (directly derived)
• Clinical use: MCH parallels MCV and tracks with it; low in hypochromic/microcytic anemias; high in macrocytic anemias. Less clinically discriminating than MCV or MCHC alone.

• Definition: Average concentration of hemoglobin per unit volume of packed red cells
• Formula: MCHC (g/dL) = Hb (g/dL) / Hct × 100
  • If Hb = 15 g/dL and Hct = 0.45 → MCHC = 15/0.45 = 33.3 g/dL
• In automated analyzers: MCHC = (Hb/Hct) × 100
• Normal: 33-36 g/dL (SI: 330-360 g/L)
• Clinical importance:
  • Decreased (<32 g/dL): Hypochromic cells - iron deficiency, thalassemia, sideroblastic anemia; MCHC can fall as low as 22 g/dL in severe IDA
  • Elevated (>36 g/dL): Almost exclusively hereditary spherocytosis (due to loss of membrane surface area, concentration of Hb in smaller cell volume); rarely exceeds 38 g/dL. An elevated MCHC on automated analyzer may also signal error (lipemia, agglutination)

• Definition: Coefficient of variation of red cell volume distribution; quantifies anisocytosis (variation in RBC size)
• Formula: RDW = (SD of MCV / Mean MCV) × 100
• Normal: 11.5-14.5%
• Elevated RDW = marked anisocytosis; earliest sign of IDA (before MCV becomes low); mixed deficiency anemias; post-treatment response (new larger cells + old small cells)
• Normal RDW with low MCV: Suggests thalassemia trait (uniform small cells, low RDW)
• Elevated RDW with low MCV: Suggests IDA

Summary Table - Index Pattern in Common Anemias

Derived Ratios Using Indices

• <13: suggests thalassemia trait (many small RBCs)

• 13: suggests iron deficiency anemia

• Negative: thalassemia trait
• Positive: IDA

---

Q5. Zeta Sedimentation Rate (ZSR)

Background - Erythrocyte Sedimentation Rate (ESR)

Zeta Sedimentation Ratio (ZSR)

1. Blood is collected and placed in a Zetafuge - a special centrifuge that alternately rotates and stops the capillary tubes, causing repetitive dispersion and settling of RBCs
2. The centrifugation process overcomes the effects of hematocrit by creating a standardized packing condition
3. The zeta potential (negative surface charge of RBCs that normally repels them) is overcome by plasma proteins → RBCs settle according to the degree of rouleaux formation
4. The ZSR = (Zeta cell volume / Hematocrit) × 100; expressed as a percentage
5. Normal ZSR: 40-51%

• Independent of hematocrit (not affected by anemia or polycythemia)
• Rapid (takes ~5 minutes vs. 60 minutes for Westergren ESR)
• Requires only a small volume of blood (~50 µL)
• More reproducible; coefficient of variation is lower

• Elevated ZSR indicates increased plasma protein (particularly fibrinogen, IgG, IgM) → acute or chronic inflammation, infection, autoimmune disease, malignancy
• Used similarly to ESR as a non-specific acute phase marker
• Particularly useful in patients with anemia (where ESR would be artificially elevated) or polycythemia (where ESR would be falsely normal)
• ZSR correlates well with ESR and with CRP and fibrinogen levels
• Normal ZSR with normal hematocrit = normal ESR

• Like ESR, it is a non-specific test; it identifies that inflammation is present but cannot identify its cause
• Not as widely available as ESR; requires specialized equipment (Zetafuge)
• Largely replaced in modern practice by CRP and other acute-phase markers

---

Q6. Disseminated Intravascular Coagulation (DIC)

Definition

Etiology / Triggers

Pathogenesis

• Obstetric accidents, cancer cells, fat emboli → TF (tissue thromboplastin) enters circulation
• Bacterial endotoxins/exotoxins → stimulate TF expression on monocytes → IL-1 and TNF-α → TF on endothelium + downregulation of thrombomodulin (reduces protein C activation)
• TF + VIIa → activates X → thrombin generation

• Endotoxins, immune complexes (SLE), heat, rickettsiae → endothelial damage → release of TF + subendothelial collagen/vWF exposure → platelet activation + intrinsic pathway activation

Trigger (TF release / endothelial injury)
↓
Systemic thrombin generation
↓
Fibrinogen → Fibrin (microthrombi throughout microcirculation)
↓
Platelet aggregation → thrombocytopenia (consumption)
Consumption of factors V, VIII, fibrinogen → coagulopathy
↓
Secondary fibrinolysis (plasminogen activators released)
Plasmin cleaves fibrin → FDPs (anti-hemostatic) + D-dimers
Plasmin also degrades factors V and VIII → worsens bleeding
↓
Dual consequences:
1. Microthrombi → organ ischemia (kidneys, adrenals, brain, lung)
2. Bleeding diathesis (consumed platelets, depleted clotting factors, FDPs inhibiting platelet aggregation and fibrin polymerization)

Morphology

• Microthrombi in arterioles and capillaries of: kidneys (glomerular fibrin thrombi → bilateral renal cortical necrosis), adrenals (Waterhouse-Friderichsen syndrome), brain (microinfarcts), heart, lungs
• Hemorrhage: petechiae and ecchymoses on skin, serosal linings, endocardium, mucosa
• Microangiopathic hemolytic anemia (MAHA): schistocytes (fragmented RBCs) from mechanical shear within fibrin-containing vessels

Clinical Features

• Acute DIC (obstetric, sepsis): dominated by bleeding - petechiae, purpura, oozing from IV sites, mucous membrane hemorrhage, hematuria
• Chronic DIC (cancer): dominated by thrombosis - DVT, superficial thrombophlebitis, arterial thrombi
• Organ dysfunction: acute renal failure (cortical necrosis), dyspnea (pulmonary microthrombi), confusion/seizures (cerebral microinfarcts), shock

Laboratory Investigations

• The DIC triad: Thrombocytopenia + Prolonged PT/aPTT/TT + Low fibrinogen + Elevated D-dimers + Schistocytes on smear

---

Q7. Von Willebrand Disease (vWD)

Introduction

1. Platelet adhesion: vWF bridges subendothelial collagen to platelet GpIb receptors (crucial for primary hemostasis, especially under high shear stress)
2. Factor VIII carrier: vWF binds and stabilizes factor VIII in plasma (protecting it from premature degradation)

Classification (Types)

• Autosomal dominant; partial quantitative deficiency of vWF (structurally normal but reduced amount)
• Mild-moderate bleeding; clinically the mildest form
• HbA2 slightly reduced; factor VIII mildly decreased but usually not clinically significant

• Autosomal recessive; near-complete absence of vWF
• Severe mucocutaneous AND joint/soft tissue bleeding (resembles hemophilia due to very low factor VIII)

• Lymphoproliferative disorders (autoantibodies against vWF)
• Myeloproliferative disorders with high platelet counts (adsorption of vWF onto platelets)
• Aortic stenosis, ventricular assist devices (increased shear → proteolysis of HMW multimers - Heyde's syndrome)
• Hypothyroidism (decreased synthesis)

Laboratory Diagnosis

• vWF:RCo / vWF:Ag ratio:
  • Normal (≥0.6): Type 1 (proportional reduction)
  • Low (<0.6): Type 2A, 2B, 2M (disproportionate loss of function)
  • Very low: Type 2A, 2B

---

Q8. Fibrinogen Assay

Biology of Fibrinogen

Indications for Fibrinogen Assay

• Evaluation of DIC (expected to be low - consumptive)
• Liver disease (decreased synthesis)
• Congenital afibrinogenemia / hypofibrinogenemia / dysfibrinogenemia
• Fibrinolytic therapy monitoring (streptokinase, tPA)
• Pre-operative assessment when bleeding is expected
• Elevated fibrinogen as a cardiovascular risk marker

Methods of Fibrinogen Measurement

• Principle: Patient plasma (diluted 1:10) is clotted with a high concentration of thrombin (50-100 U/mL - excess). Because thrombin is in large excess, the rate of clot formation is limited only by fibrinogen concentration; the more fibrinogen, the faster the clot forms; thus clotting time is inversely proportional to fibrinogen concentration
• Patient's plasma is diluted to minimize interference from heparin, FDPs, and thrombin inhibitors
• A standard calibration curve (clotting time vs. known fibrinogen concentration) is used to determine patient fibrinogen
• Advantages: Measures only functionally clottable fibrinogen; FDPs are not detected (plasma dilution prevents their interference); unaffected by heparin at standard dilutions; considers fibrinogen quality (detects dysfibrinogenemia where clottable fibrinogen is lower than total protein)
• Interference: Very high concentrations of direct thrombin inhibitors (argatroban, bivalirudin) give falsely low results

• Principle: Fibrinogen concentration is proportional to the maximal change in optical density (absorbance) during a PT measurement. A calibration curve relates change in absorbance to fibrinogen concentration
• Advantages: Automated; no extra reagent; rapid; can be calculated from routine PT
• Disadvantages:
  • Overestimates fibrinogen in DIC (FDPs contribute to turbidity), during fibrinolytic therapy, and in dysfibrinogenemia
  • Fibrinogen degradation products are detected as fibrinogen (since they still contribute to absorbance change)
  • Less reliable in severe coagulopathies
• The Clauss method is preferred in clinical situations where accuracy matters (DIC, fibrinolytic therapy)

• Radial immunodiffusion, ELISA, immunoturbidimetry: measure total fibrinogen antigen regardless of function
• Useful to diagnose dysfibrinogenemia: if functional fibrinogen (Clauss) is low but antigen is normal or high → dysfibrinogen (structural defect without quantitative deficiency)
• Afibrinogenemia: both antigen and functional fibrinogen absent
• Hypofibrinogenemia: quantitative reduction of both

• TT is related to the Clauss assay but uses a limiting (low) amount of thrombin rather than excess; thus TT is more sensitive to thrombin inhibitors, FDPs, and abnormal fibrinogens (dysfibrinogenemia)
• Reptilase time: uses reptilase (snake venom enzyme) instead of thrombin; not affected by heparin; if TT prolonged but reptilase time normal → heparin is the cause

---

Q9. Platelet Indices and Platelet Function Tests

Platelet Indices

• Normal: 150,000-400,000/µL (150-400 × 10⁹/L)
• Directly measured by impedance (electrical resistance as platelets pass through aperture) or optical (light scattering)
• Thrombocytopenia: <150,000/µL; Thrombocytosis: >400,000/µL

• Definition: Average volume of individual platelets; analogous to MCV for RBCs
• Normal: 7.5-12.5 fL (varies by analyzer and anticoagulant)
• Clinical significance:
  • Elevated MPV (large platelets): Increased platelet production / peripheral destruction (ITP, TTP); myeloproliferative disorders (essential thrombocythemia); Bernard-Soulier syndrome (giant platelets)
  • Decreased MPV: Bone marrow failure (aplastic anemia, chemotherapy); Wiskott-Aldrich syndrome (small platelets)
  • MPV inversely correlates with platelet count in destructive thrombocytopenia (low count + high MPV = peripheral destruction); both low in production failure

• Definition: Coefficient of variation (or geometric standard deviation) of platelet volume distribution; measures variability in platelet size (anisocytosis of platelets)
• Normal: 9-17%
• Elevated PDW: Indicates mixed platelet population; thrombocytopenia with active platelet turnover; hypersplenism; ITP
• PDW combined with MPV gives more information about platelet production vs. destruction

• Definition: Fraction of whole blood volume occupied by platelets; analogous to hematocrit for RBCs
• Formula: PCT = (Platelet count × MPV) / 10,000; expressed as %
• Normal: 0.18-0.36%
• Increases in thrombocytosis; useful as a quality control check

• Definition: Percentage of platelets with volume >12 fL
• Reflects proportion of large, young (recently produced) platelets
• Elevated in peripheral platelet destruction (ITP) and myeloproliferative disorders

• Definition: Percentage of newly produced (reticulated) platelets detected by RNA staining on automated analyzer (Sysmex)
• Analogous to reticulocyte count for RBCs
• Elevated IPF: Peripheral platelet destruction (ITP, TTP, DIC) - marrow is producing young platelets rapidly
• Low/normal IPF with thrombocytopenia: Decreased production (aplastic anemia, chemotherapy) → most useful clinical application
• IPF helps differentiate destructive from hypoproliferative thrombocytopenia

---

Platelet Function Tests

• Standardized incision (1 cm × 1 mm) on volar forearm under 40 mmHg cuff; time to cessation of bleeding measured
• Normal: 2.5-9.5 minutes (Ivy); varies by method
• Prolonged: Thrombocytopenia (<100,000/µL), qualitative platelet defects (vWD, Glanzmann thrombasthenia, Bernard-Soulier, drug effects), severe von Willebrand disease
• Limitations: Poorly reproducible; operator-dependent; not predictive of surgical bleeding; largely replaced by PFA-100 in modern labs

• Blood is aspirated through an aperture in a collagen/ADP or collagen/epinephrine membrane under high shear stress
• Platelets adhere and aggregate until the aperture is blocked; time to occlusion = closure time (CT)
• Normal CT (Col/ADP): <70-80 seconds; Col/Epi: <165-186 seconds
• Prolonged CT: vWD (collagen/epinephrine most sensitive), Glanzmann thrombasthenia, Bernard-Soulier, antiplatelet drugs (aspirin prolongs Col/Epi more than Col/ADP)
• Better reproducibility and automation than BT; does not detect storage pool defects well

• CD41 (GPIIb, αIIb): absent in Glanzmann thrombasthenia
• CD42b (GpIbα): absent in Bernard-Soulier syndrome
• CD62P (P-selectin, marker of α-granule release)
• CD63 (marker of dense granule release)
• PAC-1 (conformation-specific antibody to activated GPIIb/IIIa): measures platelet activation state
• Platelet surface-bound IgG: elevated in ITP

• ATP luminometry: Measures ATP secretion from dense granules using luciferin-luciferase reaction (lumi-aggregometry); reduced or absent in Hermansky-Pudlak, Chediak-Higashi, delta-SPD
• Whole mount electron microscopy (WMTEM): Gold standard for dense granule deficiency - counts electron-dense bodies

• Platelet Retraction Test: Serum is expressed from clotted blood over 1 hour; reduced in Glanzmann thrombasthenia and thrombocytopenia
• Platelet Factor 3 (PF3) Availability: Tests availability of platelet phospholipid surface for coagulation
• Thromboelastography (TEG) / ROTEM: Global viscoelastic assay assessing all three phases of hemostasis including platelet contribution (MA = maximum amplitude reflects platelet-fibrin interaction strength); used perioperatively and in trauma to guide transfusion

---

---

CLINICAL BIOCHEMISTRY & LABORATORY MEDICINE - COMPREHENSIVE ANSWERS

---

Q1. Chemiluminescence

Definition

Principle

Key Chemiluminescent Compounds

Types of Chemiluminescence-based Immunoassays (CLIA)

• Acridinium ester is directly conjugated to the antibody/antigen label
• Triggered by alkaline H₂O₂ → instantaneous flash of light measured by photomultiplier tube (PMT)
• Very fast; high sensitivity; minimal background

• Luminol + horseradish peroxidase (HRP) + H₂O₂ + enhancers (e.g., para-iodophenol)
• Enhancers increase signal intensity and duration
• Used in ELISA-based systems

• Ruthenium chelate label + tripropylamine (TPA) as co-reactant
• Electrochemical excitation: voltage applied to electrode → Ru³⁺ (oxidized) + TPA → excited Ru²⁺* → emits light at 620 nm
• Repeated cycling of the reaction amplifies signal
• Used in Roche Elecsys/cobas platforms
• Advantages: highly sensitive, rapid, stable labels, wide dynamic range

• Used in research and some assay formats

Applications in Laboratory Medicine

Advantages over Radioimmunoassay (RIA) and ELISA

Chemiluminescence vs. Fluorescence

• Fluorescence requires external excitation light source (excitation → emission); background fluorescence from sample is a major problem
• Chemiluminescence generates its own light via chemical reaction; no external light source; hence virtually zero background = superior signal-to-noise ratio

---

Q2. Serological Tests in Syphilis

Classification of Tests

Syphilis Serology
│
├── Non-Treponemal Tests (screening)
│   ├── VDRL (Venereal Disease Research Laboratory)
│   └── RPR (Rapid Plasma Reagin)
│
└── Treponemal Tests (confirmatory)
    ├── TPHA (Treponema pallidum Haemagglutination Assay)
    ├── FTA-ABS (Fluorescent Treponemal Antibody Absorption)
    ├── TPI (Treponema pallidum Immobilization)
    ├── TPPA (T. pallidum Particle Agglutination)
    └── CLIA/EIA Treponemal assays (modern platforms)

Non-Treponemal Tests

• Patient's inactivated serum + VDRL antigen (cardiolipin-lecithin-cholesterol)
• Positive: flocculation (clumping) - read microscopically
• Reported as: Non-reactive / Reactive (weakly, reactive, strongly reactive)
• Also quantified by dilution titer (e.g., 1:8, 1:16) - titer correlates with disease activity
• Can be performed on CSF (VDRL is the only accepted test for neurosyphilis on CSF)
• Becomes positive: 1-2 weeks after chancre appears

• Similar principle to VDRL but uses carbon particles as visible indicator → read macroscopically (naked eye) without microscope
• More practical for field/screening use
• Equivalent sensitivity to VDRL but slightly less specific

1. Screening for syphilis
2. Monitoring treatment response - titer should fall 4-fold after adequate treatment (e.g., 1:32 → 1:8) and eventually become non-reactive
3. Assessment of disease activity - high titers indicate active disease

---

Treponemal Tests

• Patient serum is absorbed with Reiter's treponeme (non-pathogenic) to remove cross-reactive antibodies
• Absorbed serum is overlaid on T. pallidum antigen on slide
• Anti-treponemal antibodies bind → FITC-labeled anti-human IgG added → fluorescence read under fluorescence microscope
• Most sensitive treponemal test; becomes positive in primary syphilis even before VDRL
• Gold standard for confirmation
• IgM-FTA-ABS: Used to diagnose congenital syphilis in neonates (IgM cannot cross placenta - neonatal IgM = neonatal infection)

• T. pallidum antigens coat red blood cells (TPHA) or gelatin particles (TPPA)
• Patient antibodies cause haemagglutination/agglutination
• Simple, inexpensive, suitable for large-scale screening
• Less sensitive than FTA-ABS in primary syphilis

• Live, motile T. pallidum + patient serum + complement → specific antibody + complement immobilizes treponemes
• Most specific treponemal test; historically the "gold standard"
• Now obsolete (requires live organisms, technically complex)

• Recombinant T. pallidum proteins (TpN17, TpN15, TpN47) as antigens
• Fully automated; used for high-throughput screening
• Some labs now use "Reverse algorithm": screen with EIA/CLIA treponemal → confirm positives with non-treponemal (VDRL/RPR) to assess activity

Algorithm for Syphilis Testing

1. Screen with non-treponemal (RPR or VDRL)
2. If reactive: confirm with treponemal test (FTA-ABS or TPPA)
3. If both positive: syphilis confirmed - treat and monitor with non-treponemal titers

1. Screen with automated treponemal EIA/CLIA
2. If reactive: reflexed to quantitative RPR/VDRL
3. If RPR/VDRL non-reactive: confirmatory with second treponemal (TPPA) to resolve discordant results

Syphilis Stage and Serology

---

Q3. Dry Chemistry - Advantages and Disadvantages

Definition

Technology Platforms

• Kodak Ektachem (Vitros): Multi-layered analytical elements (slides); each layer performs a specific function (spreading, filtering, reagent zone, indicator zone)
• Reflotron, DT-60: Dry reagent strips for individual tests
• Urine dipsticks: Simplest form of dry chemistry

How Dry Chemistry Works

1. A small volume of sample (e.g., 10 µL serum) is applied to the slide/strip
2. Sample migrates through multiple layers: spreading layer → filtering/separation layer → reagent layer
3. Chemical reaction produces a colored product in the indicator layer
4. Reflectance photometer measures light reflected off the surface at appropriate wavelength
5. Concentration calculated from % reflectance using the Kubelka-Munk equation

Advantages of Dry Chemistry

Disadvantages of Dry Chemistry

---

Q4. Proteomics - Definition and Role in Disease Prognosis

Definition

Components of Proteomics

Key Technologies

Role of Proteomics in Disease Prognosis

• Plasma proteomics identifies novel markers for heart failure prognosis: BNP, NT-proBNP, troponin I/T, cystatin C, galectin-3
• Fibrinogen variants and apolipoproteins as risk predictors

• Alzheimer's disease: CSF proteomics: Aβ42/Aβ40 ratio, phospho-tau (p-tau 181, p-tau 217), total tau; predict conversion from MCI to AD
• Parkinson's disease: α-synuclein proteoforms in CSF; DJ-1 protein
• Blood-based proteomics for non-invasive biomarkers (GFAP, NFL)

• Proteomic profiling of plasma identifies cytokines, complement proteins, coagulation factors that predict organ failure, ICU mortality (APACHE score augmentation)
• Lactoferrin, HMGB1, presepsin as prognostic markers

• Rheumatoid arthritis: ACPA (anti-citrullinated protein antibodies) identified by proteomics
• Lupus: anti-dsDNA, anti-Sm, complement levels; urinary proteomics for lupus nephritis activity/prognosis

• Pathogen proteomics for identifying virulence factors
• Host response proteomics predicts severity of COVID-19, tuberculosis reactivation

• Predicting drug response and toxicity based on protein expression profiles
• Identifying drug targets and resistance mechanisms

Challenges in Clinical Proteomics

• Serum/plasma proteome dominated by abundant proteins (albumin, IgG) masking low-abundance disease markers
• High variability (pre-analytical: sample handling, freeze-thaw cycles)
• Lack of standardization across platforms
• Complex bioinformatic analysis required
• Translation from discovery to validated clinical assay is slow and expensive

---

Q5. Serum Enzymes as Diagnostic Tools

Principles

• Enzymes are intracellular proteins released during cell death, membrane damage, or increased cell turnover
• Measured by their catalytic activity (units/L) at standardized conditions (pH, temperature, substrate)
• Elevated in disease; some enzymes are organ-specific (high specificity)

Major Diagnostic Enzymes

• Reaction: Amino group transfer to oxaloacetate (AST) or pyruvate (ALT) → forms glutamate
• AST/ALT ratio (De Ritis ratio):
  • <1 (ALT > AST): Viral hepatitis (cytoplasmic injury), NAFLD

  • 2 (AST > ALT): Alcoholic hepatitis (mitochondrial damage releases AST), cirrhosis, muscle disease

• Most elevated in: acute hepatocellular necrosis (viral hepatitis: >1000 U/L; up to 100× normal)

• Sources: Liver (canalicular membrane), bone (osteoblasts), intestine, placenta, kidney
• Normal: 44-147 U/L (adult); higher in children and pregnancy (physiologic)
• Markedly elevated (>3× normal) in: cholestatic jaundice, bone disease (Paget's, metastases, rickets), pregnancy
• Liver vs. bone ALP distinguished by: GGT (elevated with liver ALP; normal with bone ALP); ALP isoenzyme electrophoresis; heat stability (bone ALP heat-labile at 56°C)

• Sources: Liver, kidney, pancreas; liver-specific in practice
• Normal: 5-55 U/L
• Very sensitive marker for hepatobiliary disease, especially alcoholic liver disease and cholestasis
• Induced by: alcohol, phenytoin, barbiturates, rifampicin (enzyme induction)
• Used as: surrogate for alcohol abuse; confirmation that elevated ALP is hepatic in origin

• Ubiquitous cytoplasmic enzyme; found in heart, liver, RBC, kidney, muscle, lung
• Normal: 140-280 U/L
• Five isoenzymes (LDH1-LDH5):
  • LDH1 (HHHH): heart, RBC - predominant in MI, hemolysis
  • LDH2: heart/RBC (similar to LDH1)
  • LDH3: lung, lymphocytes
  • LDH4: kidney, liver
  • LDH5 (MMMM): liver, skeletal muscle
• LDH1 > LDH2 (flip pattern): Acute myocardial infarction (historical), hemolytic anemia
• Markedly elevated in: megaloblastic anemia, hemolysis, malignancy, acute MI, pulmonary infarction, liver necrosis

• Sources: Skeletal muscle (CK-MM), heart (CK-MB), brain (CK-BB)
• Normal: 55-170 U/L (men); 30-135 U/L (women)
• Isoenzymes:
  • CK-MM (CK3): 96-100% in normal serum; skeletal muscle injury (trauma, rhabdomyolysis, IM injections, hypothyroidism, Duchenne muscular dystrophy)
  • CK-MB (CK2): Normally <5% of total CK; elevated in acute MI (rises 3-6 hrs, peaks 12-24 hrs, normalizes 48-72 hrs); also elevated in myocarditis, cardiac surgery
  • CK-BB (CK1): Not detected in normal serum; elevated in brain injury (stroke, head trauma), gut infarction, small cell lung cancer
• CK-MB mass assay and CK-MB/total CK ratio >5-6% suggest myocardial origin
• Macro-CK: CK-BB bound to IgG or mitochondrial CK dimer; false elevation

• Sources: Pancreas (p-amylase, 40%), salivary glands (s-amylase, 60%)
• Normal: 30-110 U/L
• Elevated in: Acute pancreatitis (rises within 2-12 hours; normalizes 3-5 days), salivary gland disease (mumps), intestinal obstruction, ectopic pregnancy, renal failure (decreased clearance)
• Less sensitive and specific than lipase for pancreatitis
• Amylase isoforms: p-type vs. s-type distinguished by electrophoresis or inhibition assay

• Source: Pancreas (highly specific)
• Normal: 0-160 U/L
• Rises later than amylase (12-24 hrs), remains elevated longer (7-14 days)
• More specific than amylase for acute pancreatitis
• Lipase/amylase ratio: >3 in alcoholic pancreatitis (useful in adults)

• Synthesized by liver; reflects hepatic synthetic function
• Decreased in: liver disease (cirrhosis, hepatitis), organophosphate poisoning
• Used to monitor severity of liver disease; pre-anesthetic assessment (succinylcholine metabolism)

• Liver-specific enzyme (canalicular membrane)
• Elevated in cholestasis but NOT in bone disease
• Used to confirm hepatic origin of elevated ALP (if both elevated = liver source)

• Present in muscle and liver
• Elevated in: myopathies, Duchenne muscular dystrophy, viral hepatitis
• Less commonly used than CK

Pattern Recognition

---

Q6. Diabetes Mellitus - Classification, Lab Diagnosis, HbA1c, and Complications

Classification (WHO/ADA 2024)

1. Type 1 DM - Autoimmune destruction of β-cells; absolute insulin deficiency; anti-GAD, anti-IA2, anti-ZnT8 antibodies
2. Type 2 DM - Insulin resistance + relative insulin deficiency; most common (>90%)
3. Gestational DM (GDM) - Glucose intolerance first detected during pregnancy
4. Other specific types - MODY (maturity-onset diabetes of the young; HNF1A, HNF4A, GCK gene mutations), drug-induced (steroids, thiazides), pancreatic disease

Diagnostic Criteria (ADA 2024)

Pre-diabetes (Impaired Glucose Regulation)

---

Glycosylated Hemoglobin (HbA1c)

• HbA1a: glycated with fructose-1,6-diphosphate
• HbA1b: glycated with pyruvate
• HbA1c: glycated with glucose (clinically relevant; 70-80% of total HbA1)

• Normal: <5.7% (<39 mmol/mol)
• Pre-diabetes: 5.7-6.4% (39-47 mmol/mol)
• Diabetes: ≥6.5% (≥48 mmol/mol)
• Treatment target: <7.0% (53 mmol/mol) for most adults; <8.0% for elderly/comorbid

• Formula: eAG (mg/dL) = 28.7 × HbA1c (%) - 46.7
• 7% HbA1c ≈ 154 mg/dL eAG

• Fructosamine: Glycated albumin; reflects glucose control over past 2-3 weeks; useful when HbA1c unreliable (hemolytic anemia, rapid glucose changes in pregnancy)
• Glycated albumin (GA): 2-3 week average; more useful in dialysis, pregnancy
• 1,5-Anhydroglucitol (1,5-AG): Short-term (1-2 weeks) marker; decreases when postprandial glucose spikes occur; sensitive marker for glucose excursions

---

Complications of DM and Laboratory Monitoring

• DKA (Type 1): Blood glucose >250 mg/dL; pH <7.3; bicarbonate <15 mEq/L; ketones in blood/urine; elevated anion gap (AG = Na - [Cl + HCO₃], normal 8-12 mEq/L; >20 in DKA)
  • Beta-hydroxybutyrate (preferred over urine ketones - more sensitive); elevated; serum osmolality
• HHS (Hyperosmolar Hyperglycemic State - Type 2): Glucose >600 mg/dL; serum osmolality >320 mOsm/kg; minimal/no ketosis; pH normal

---

Q7. Laboratory Support for Thyroid Disease Diagnosis and Monitoring

Thyroid Physiology Recap

Primary Laboratory Tests

• Most sensitive single test for thyroid function
• Measured by immunometric (sandwich) assay; third/fourth generation: sensitivity 0.001-0.01 mIU/L
• Normal: 0.4-4.0 mIU/L
• TSH is inversely and logarithmically related to free T4 (log-linear relationship)
• Elevated TSH = hypothyroidism (primary)
• Suppressed TSH = hyperthyroidism; also pituitary/hypothalamic disease
• Subclinical hypothyroidism: TSH elevated, fT4 normal
• Subclinical hyperthyroidism: TSH suppressed, fT4/fT3 normal

• Direct measure of biologically active T4
• Normal: 0.8-1.8 ng/dL (10-23 pmol/L)
• Elevated in hyperthyroidism; decreased in hypothyroidism
• Not affected by changes in TBG (unlike total T4)

• Normal: 2.3-4.2 pg/mL (3.5-6.5 pmol/L)
• Particularly useful for T3-toxicosis (hyperthyroid patients with normal fT4 but elevated fT3)

• Affected by TBG levels (elevated in pregnancy, OCP use, hepatitis - elevated TBG; nephrotic syndrome, androgens, liver disease - decreased TBG)

Second-Line Tests

• Synthesized exclusively by thyroid tissue
• Used to monitor recurrence after thyroidectomy for differentiated thyroid cancer (papillary, follicular)
• Must be measured alongside anti-Tg antibodies (interference: anti-Tg antibodies falsely lower Tg)
• Stimulated Tg (after thyroid hormone withdrawal or rhTSH injection) is more sensitive for detecting residual disease

• Secreted by C cells of thyroid
• Elevated in medullary thyroid carcinoma (MTC)
• Screening test for MTC in patients with thyroid nodules; genetic testing for RET mutations (MEN2)

• Not a biochemical test but guided by lab findings
• For suspicious thyroid nodules detected on USS

Patterns of Results

Monitoring Thyroid Disease

• Hypothyroidism on thyroxine: TSH every 6-12 months after dose stabilization; fT4 for pituitary disease
• Hyperthyroidism on antithyroid drugs (carbimazole/PTU): TFTs every 4-6 weeks until euthyroid, then 3-monthly; TRAb before stopping drugs (predicts relapse)
• Thyroid cancer follow-up: Stimulated Tg + neck USS + anti-Tg antibodies annually

---

Q8. Laboratory Investigations of Jaundice

Definition

Bilirubin Metabolism

Classification

Laboratory Investigations

• CBC: anemia, reticulocytosis
• Peripheral smear: spherocytes (AIHA, HS), sickle cells, schistocytes (MAHA)
• Serum haptoglobin: decreased
• LDH: elevated
• Direct Coombs test: positive in AIHA
• Osmotic fragility: elevated in hereditary spherocytosis

• HBsAg, anti-HCV, anti-HAV IgM, EBV, CMV

• Liver USS: dilated bile ducts (obstructive), hepatomegaly, gallstones, mass lesions
• CT/MRCP: biliary anatomy, pancreatic mass, choledocholithiasis

• When non-invasive tests are inconclusive
• Differentiates hepatitis from cirrhosis, granulomatous hepatitis, PBC, Wilson's disease

---

Q9. Tumor Hormonal Markers

Classification

Major Tumor Markers

• Glycoprotein produced exclusively by prostate epithelium
• Normal: <4.0 ng/mL (but age-specific reference ranges preferred)
• PSA density = PSA/prostate volume (by USS); >0.15 ng/mL/mL suspicious
• PSA velocity: >0.75 ng/mL/year = suspicious
• Free PSA / Total PSA ratio: <10% suggests carcinoma; >25% suggests benign prostatic hyperplasia (BPH)
• PSA elevated in: cancer, BPH, prostatitis, DRE, ejaculation (transient)

General Principles of Tumor Markers

---

Q10. Laboratory Investigations in Infertility

Male Infertility Investigations (see also Q20)

• Volume, sperm count, motility, morphology

• Karyotype: Klinefelter syndrome (47,XXY) - most common genetic cause of azoospermia
• Y-chromosome microdeletion (AZFa, AZFb, AZFc regions): critical for ICSI planning
• CFTR mutation: bilateral absence of vas deferens (CBAVD) → obstructive azoospermia

• Testicular biopsy: distinguishes obstructive from non-obstructive azoospermia
• Sperm DNA fragmentation index (DFI): >25% associated with recurrent pregnancy loss, IVF failure
• Anti-sperm antibodies (ASA): >50% motile sperm coated with IgA/IgG in MAR test or direct immunobead test
• Scrotal USS: varicocele, testicular masses
• Trans-rectal USS: ejaculatory duct obstruction

Female Infertility Investigations

• Midluteal phase progesterone (Day 21): >3 ng/mL = ovulation occurred; >10 ng/mL = good luteal function
• LH surge detection (urine LH kits): surge precedes ovulation by 24-36 hours
• Basal body temperature (BBT) chart: Rise of 0.2-0.5°C after ovulation
• Endometrial biopsy: Secretory transformation confirms ovulation (historical)

• LH/FSH ratio >2, elevated free testosterone, low SHBG, elevated DHEA-S, elevated AMH (>3.5 ng/mL)
• Fasting insulin, glucose → insulin resistance (HOMA-IR)
• Prolactin, TSH (to exclude secondary causes)
• Pelvic USS: polycystic ovary morphology (≥12 follicles 2-9mm per ovary or ovarian volume >10 mL)

• Hysterosalpingography (HSG): tubal patency, uterine cavity
• Hysteroscopy, laparoscopy (gold standard for endometriosis)
• Saline infusion sonography (SIS)

• Anti-phospholipid antibodies (lupus anticoagulant, anti-cardiolipin IgG/IgM, anti-β2GPI): cause recurrent miscarriage, not typically primary infertility
• Anti-nuclear antibody (ANA) screen
• Anti-ovarian antibody (autoimmune premature ovarian insufficiency)

• Karyotype: Turner syndrome (45,X), X-chromosome deletions (POI)
• FMR1 premutation: Fragile X - associated with premature ovarian insufficiency
• BRCA testing if strong family history (ovarian reserve may be reduced)

• Karyotype (both partners)
• Anti-phospholipid antibody syndrome panel
• Thrombophilia screen: Factor V Leiden, prothrombin gene mutation (G20210A), protein C/S, antithrombin
• TSH, prolactin, fasting glucose

---

Q11. Liver Function Tests (LFT) and Serological Markers of Hepatitis

Liver Function Tests

• ALT (SGPT): Most specific for hepatocellular injury; liver-specific
• AST (SGOT): Less specific (heart, muscle, kidney, RBC also)
• Both measure aminotransferase activity (U/L)

• ALP (Alkaline phosphatase): Elevated in cholestasis and bone disease
• GGT: Elevated in cholestasis, alcohol, enzyme inducers; confirms hepatic origin of ALP
• Direct and total bilirubin (see Q8)

• Serum ammonia: Elevated in hepatic encephalopathy (liver failure, portosystemic shunting)
• Serum bile acids: Very sensitive marker of hepatocellular function (not routinely done)

• Serum protein electrophoresis: Gamma-globulin bridging in cirrhosis (↑ immunoglobulins)
• Platelet count: Low in cirrhosis (hypersplenism + reduced TPO synthesis)
• FibroScan (elastography): Non-invasive liver stiffness measurement (not biochemical)
• FIB-4 index = [Age × AST] / [Platelets × √ALT]: >3.25 suggests advanced fibrosis
• APRI (AST:Platelet Ratio Index): >2.0 suggests cirrhosis

---

Serological Markers of Hepatitis

---

---

---

• Requires HBsAg for replication (incomplete RNA virus)
• Anti-HDV IgM: acute delta superinfection/coinfection
• HDV RNA: active replication
• Coinfection (HBV + HDV simultaneously): usually self-limited
• Superinfection (chronic HBV + HDV): often severe, rapid progression to cirrhosis

• Anti-HEV IgM: acute HEV infection
• Anti-HEV IgG: past infection/immunity
• HEV RNA: active replication (zoonotic genotypes 3/4 in immunocompromised)
• Causes acute hepatitis; fulminant in pregnancy (genotype 1/2); mortality 15-25% in pregnancy

---

Q12. Renal Function Tests (RFT)

Overview

Glomerular Function Tests

• End-product of creatine/phosphocreatine metabolism in muscle
• Completely filtered, minimal tubular secretion (10-15%)
• Normal: 0.6-1.2 mg/dL (men); 0.5-1.0 mg/dL (women)
• Limitations: Affected by muscle mass (falsely low in elderly, women, malnutrition; falsely high in bodybuilders); does not rise above normal until ~50% nephron loss (insensitive early)
• Measured by: Jaffe (alkaline picrate; non-specific - creatinogen interferes) or enzymatic methods (more specific)

• End-product of protein catabolism; synthesized in liver
• Normal urea: 7-25 mg/dL (as BUN); 2.5-6.4 mmol/L
• BUN:Creatinine ratio:
  • 10:1 to 20:1 = normal

  • 20:1 = Pre-renal (dehydration, cardiac failure, GI bleeding with protein load, steroids, high protein diet)

  • <10:1 = Liver disease (↓ urea synthesis), low protein diet, acute tubular injury (urea rises less than creatinine)

• Low MW (13 kDa) protein; constitutively produced by all nucleated cells; freely filtered by glomerulus; completely reabsorbed and degraded by proximal tubule (not secreted)
• Not affected by muscle mass, sex, or diet
• More sensitive than creatinine for early CKD detection
• Used in combined creatinine + cystatin C eGFR equations

Tubular Function Tests

• Normal urine osmolality: 50-1200 mOsm/kg (wide range reflects concentrating/diluting ability)
• Specific gravity: 1.001-1.035
• Fixed specific gravity (~1.010) = isosthenuria = loss of concentrating ability (severe tubular disease)
• Urine:plasma osmolality ratio: >2 = concentrated (normal); <1.1 = isosthenuria

• Distinguishes central DI, nephrogenic DI, and primary polydipsia
• After water deprivation: urine osmolality remains low in DI; rises in primary polydipsia
• After DDAVP: urine osmolality rises in central DI; no response in nephrogenic DI

• 24-hour urine protein: normal <150 mg/day; nephrotic range >3.5 g/day
• Spot urine protein:creatinine ratio: equivalent to 24-hr; normal <0.2 mg/mg
• Urine albumin:creatinine ratio (ACR): normal <30 mg/g; microalbuminuria 30-300; macroalbuminuria >300

Electrolyte and Acid-Base Tests

• Na, K, Cl, HCO₃, Ca, PO₄, Mg: essential in renal disease
• Hyperkalemia: major complication of renal failure; cardiac arrhythmias
• Hyponatremia: SIADH, fluid overload
• Metabolic acidosis: low HCO₃, high anion gap (uremic acids in CKD)

• FENa = (UNa × SCr) / (SNa × UCr) × 100
• FENa <1%: pre-renal acute kidney injury (tubular reabsorption intact)
• FENa >2%: intrinsic renal (ATN) - tubules cannot reabsorb sodium

• Nephrolithiasis workup: hypercalciuria, hyperuricosuria, oxaluria
• 24-hour urine collection for stone risk assessment

---

Q13. Point of Care Testing (POCT)

Definition

Advantages

Disadvantages / Challenges

Common POCT Tests and Technologies

Regulatory Framework (CLIA 88)

• Waived tests: Simple, low risk, FDA-cleared (e.g., urine dipstick, glucose)
• Moderate complexity: More oversight; QC required
• High complexity: Requires laboratory director, documented training
• Provider-Performed Microscopy (PPM): Wet preparations, KOH preparations, urine sediment

---

Q14. Glucose Tolerance Test (GTT)

Types

Standard 75g OGTT (WHO Criteria)

• Carbohydrate-rich diet (≥150 g/day) for at least 3 days prior
• Overnight fast of 8-10 hours (water allowed)
• No smoking, exercise, or medications affecting glucose during test
• Patient must be ambulatory (not acutely ill)

1. Fasting sample: Venous blood + urine collected (0 min)
2. Glucose load: 75g anhydrous glucose in 250-300 mL water consumed over 5 minutes
3. 2-hour sample: Venous blood + urine at 120 minutes (additional samples at 30, 60, 90 min optional)

• Glucose peaks at 30-60 minutes (usually <160-180 mg/dL)
• Returns to fasting by 2 hours
• No glycosuria (glucose threshold for kidney ~180 mg/dL)

Gestational Diabetes Testing

• 50g glucose → 1-hour plasma glucose
• ≥140 mg/dL (or ≥130 mg/dL for higher sensitivity) → proceed to Step 2

• Fasting ≥95, 1-hr ≥180, 2-hr ≥155, 3-hr ≥140 mg/dL
• GDM diagnosed if ≥2 values met or exceeded

• 75g OGTT; GDM if fasting ≥92, 1-hr ≥180, 2-hr ≥153 mg/dL (any ONE value)
• More sensitive; detects more GDM

Intravenous GTT (IVGTT)

• 0.5 g/kg body weight glucose IV → serial glucose at 0, 10, 20, 30, 40, 50, 60 min
• Calculates glucose disappearance rate (K value)
• Normal K: >1.2%/min
• Used when OGTT unreliable (malabsorption, post-gastrectomy)

---

Q15. Biosafety Measures and Waste Disposal in Laboratory

Biosafety Levels (BSL)

Standard (Universal) Precautions

• Gloves for any contact with blood/body fluids
• Gowns/aprons when splashing expected
• Eye protection/face shields for aerosol-generating procedures
• Masks when splash or aerosol risk
• Hand hygiene before and after patient contact; after removing gloves (WHO 5 moments)
• Safe handling of sharps - no recapping of needles; safety-engineered sharps devices; puncture-resistant sharps containers

Specific Safety Practices in Laboratory

• Laboratory coats (fluid-resistant), gloves (double-gloving for high-risk), safety goggles, closed-toe shoes, hair tied back
• No eating, drinking, applying cosmetics in laboratory area

• Class I: Open front; inward airflow protects worker; HEPA filtration of exhaust; no product protection
• Class II A2: Most common; recirculates 70% of air through HEPA; 30% exhausted; protects worker, product, environment
• Class II B2: 100% exhausted to outside; for volatile chemicals + biologicals
• Class III: Totally enclosed; glove box; maximum containment (BSL-4)

• Chemical disinfectants: 10% sodium hypochlorite (bleach) - most common; 70% isopropyl alcohol; glutaraldehyde 2%; formaldehyde 10%; phenolics
• Autoclave (steam sterilization): 121°C, 15 psi, 15-20 min - for biohazardous waste, instruments, media
• Dry heat: 160-180°C for glass/metal that cannot be autoclaved
• Germicidal UV: surfaces; not for liquids

• Immediately wash wound with soap and water (>15 min)
• Report to occupational health/supervisor immediately
• Risk assess source patient (HIV, HBV, HCV status)
• HIV PEP (post-exposure prophylaxis): must be started within 72 hours if source HIV+; tenofovir + emtricitabine + dolutegravir × 28 days
• HBV prophylaxis: HBIg + HBV vaccine if unvaccinated/non-immune
• Baseline and follow-up serology (HIV, HBV, HCV) at 0, 6 weeks, 3 months, 6 months

Biomedical Waste Disposal (As per Biomedical Waste Rules)

• Segregation at point of generation (most important principle)
• Never overfill containers (3/4 full maximum)
• Label: biohazard symbol, date generated, type of waste, institution name
• Transport in leak-proof, labeled bags; closed vehicles
• Records maintained for waste quantity, treatment, disposal
• All healthcare workers trained on waste segregation

---

Q16. Pregnancy Tests

Basis

• Detectable in serum: 8-10 days post-conception (before missed period)
• Doubles every 48-72 hours in normal early pregnancy
• Peaks at 8-10 weeks (~100,000 mIU/mL)
• Declines to steady level (~10,000-20,000 mIU/mL) by mid-pregnancy
• Detectable in urine: from ~12-14 days post-conception (10-20 mIU/mL threshold)

Types of Pregnancy Tests

• Lateral flow immunochromatography (immunoassay strip)
• Anti-hCG antibodies in two zones: test line and control line
• First morning urine preferred (concentrated); any urine acceptable
• Sensitivity: 10-25 mIU/mL; positive from ~1 week after missed period
• False negatives: Too early; dilute urine (drink excess water); hook effect (very high hCG saturates antibodies in ectopic or trophoblastic disease)
• False positives: Recent pregnancy, gestational trophoblastic disease, heterophile antibodies, LH cross-reactivity (perimenopausal women - LH surge)

• Most sensitive; detects as low as 1-2 mIU/mL
• Used for: confirmation of pregnancy, ectopic pregnancy workup, gestational trophoblastic disease management, monitoring miscarriage/ectopic
• Serial β-hCG: Rises ≥66% in 48 hours = normal IUP; <66% = ectopic or non-viable IUP; falls = complete miscarriage

• Positive/negative only; threshold ~20-25 mIU/mL
• Used in emergency settings

• Latex agglutination / HAI: Anti-hCG coated particles; if hCG in urine → inhibits agglutination = positive (no agglutination = pregnant)
• Largely replaced by immunochromatographic tests

• Very sensitive; now replaced by CLIA

hCG in Non-Obstetric Conditions

---

Q17. Spectrometry (Spectrophotometry)

Definition

Beer-Lambert Law (Foundation)

• A = Absorbance (optical density; dimensionless)
• ε = Molar absorption coefficient (L/mol/cm) - specific for a given substance at a given wavelength
• c = Concentration (mol/L)
• l = Path length of light through sample (cm; typically 1 cm)

Components of a Spectrophotometer

• Visible (400-700 nm): Tungsten-halogen lamp
• UV (200-400 nm): Deuterium or hydrogen lamp
• Near-IR: Tungsten lamp
• Modern instruments: LED arrays for specific wavelengths

• Prism: Refracts light; separates wavelengths by refractive index
• Diffraction grating: Reflects light at different angles based on wavelength; most widely used
• Interference filter: Narrow band pass filter; simple and cheap for specific wavelengths
• Diode array: Multiple photodiodes measure multiple wavelengths simultaneously (no moving parts)

• Photodiode, photomultiplier tube (PMT) - converts photons to electrical signal
• Charge-coupled device (CCD) in diode-array instruments

Types of Spectrophotometry

Clinical Applications

---

Q18. C-Reactive Protein (CRP)

Definition

Structure and Origin

• Pentameric (five identical noncovalently bound subunits, each 23 kDa)
• Calcium-dependent ligand binding
• Binds phosphocholine residues on bacterial cell walls (especially Streptococcus pneumoniae) and damaged cells → activates complement (classical pathway) and opsonizes pathogens
• Gene: chromosome 1q23.2

Regulation

Normal Values

• Standard CRP: <10 mg/L (or <1 mg/dL)
• High-sensitivity CRP (hs-CRP): <1 mg/L (detects concentrations 0.1-10 mg/L)

Methods of Measurement

1. Immunoturbidimetry / Immunonephelometry: Anti-CRP antibodies + sample → light scatter proportional to CRP concentration; automated; most widely used
2. ELISA: For hs-CRP; sandwich ELISA
3. Rapid immunochromatography (lateral flow): POC CRP testing
4. Particle-enhanced immunoturbidimetry: For hs-CRP; latex particles coated with anti-CRP antibodies

Clinical Applications

• Bacterial infections: CRP often >100 mg/L; higher than in viral infections
• Viral infections: CRP usually <20-40 mg/L (but can be higher in severe viral infection)
• CRP serial measurements guide antibiotic therapy duration and response

• CRP >100 mg/L: strongly suggests bacterial; CRP <20 mg/L: more likely viral (not absolute)
• PCT (procalcitonin) is more specific for bacterial sepsis

• CRP rises 12-24 hours after onset; serial measurements (0 and 24 hours) improve sensitivity
• Normal at birth; >10 mg/L at 24 hours suggests infection

• CRP rises post-surgery (normal response); failure to fall or secondary rise = infection/anastomotic leak

• CRP correlates with Crohn's disease activity (markedly elevated) but less sensitive in UC
• CRP >100 mg/L in UC = severe attack (Truelove-Witts criteria)

• hs-CRP adds prognostic information beyond traditional risk factors (Framingham score)
• JUPITER trial: Rosuvastatin reduces CRP and cardiovascular events in patients with elevated hs-CRP but normal LDL
• Used in Reynolds Risk Score for CVD risk calculation

• RA: CRP correlates with disease activity; DAS28 scoring includes CRP
• SLE: CRP often paradoxically LOW during lupus flares (anti-CRP antibodies; interferon suppresses CRP production) - EXCEPTION: elevated CRP in SLE suggests bacterial infection superimposed

---

Q19. Laboratory Investigations in Autoimmune Diseases

Principles

General Screening Tests

• Method: Indirect immunofluorescence (IIF) on HEp-2 cells (human epithelioma cells); most sensitive
• Positive titer: ≥1:80 (≥1:160 in many labs)
• Patterns (by IIF microscopy):

Disease-Specific Autoantibodies

• Anti-SSA/Ro (90%) + Anti-SSB/La (60-70%) - diagnostic
• Also: ANA, RF, elevated globulins (polyclonal hypergammaglobulinemia)
• Schirmer's test (tear production), minor salivary gland biopsy (focal lymphocytic sialadenitis)

• Anti-Jo-1 (anti-histidyl tRNA synthetase): antisynthetase syndrome (ILD + myositis + mechanic's hands + Raynaud's + arthritis)
• Anti-Mi-2: classical dermatomyositis (heliotrope rash, Gottron's papules); good prognosis
• Anti-MDA5: rapidly progressive ILD; amyopathic DM
• Anti-SRP: severe necrotizing myopathy
• CK markedly elevated (muscle breakdown); EMG/MRI/biopsy for diagnosis

• Lupus anticoagulant (LAC): DRVVT (dilute Russell viper venom time); prolonged aPTT; not corrected by mixing study
• Anti-cardiolipin IgG/IgM (aCL): ELISA; medium-high titre significant
• Anti-β2-glycoprotein I IgG/IgM (anti-β2GPI): most specific
• Positive on ≥2 occasions, ≥12 weeks apart for diagnosis
• Clinical: arterial/venous thrombosis, recurrent pregnancy loss

Complement Studies

• C3, C4: consumed in immune complex disease (SLE active) → low C3, C4
• CH50 (total hemolytic complement): reflects total complement activity
• Low C3/C4 + active lupus nephritis = poor prognostic sign

Other Useful Tests

• Inflammatory markers: ESR, CRP (CRP paradoxically low in SLE flares)
• CBC: Hemolytic anemia (positive Coombs), leukopenia, thrombocytopenia in SLE
• Immunoglobulins: Polyclonal hypergammaglobulinemia in Sjögren's, SLE; IgA deficiency in some autoimmune diseases
• Urinalysis: Proteinuria, hematuria, RBC casts in lupus nephritis

---

Q20. Seminogram and Automation in Semen Analysis

Semen Analysis (Seminogram)

Physical Parameters

Sperm Parameters (WHO 2021 Reference Limits)

Sperm Morphology Classification (Strict Kruger/Tygerberg Criteria)

• Defects of head: Large, small, tapered, pyriform, round (globozoospermia), amorphous, vacuolated heads
• Defects of midpiece: Asymmetric insertion, bent, thick, absent
• Defects of tail: Short, coiled, hairpin, multiple, stump

Nomenclature

Additional Semen Tests

Automation in Semen Analysis

• HTM-IVOS (Hamilton Thorne), SCA (Sperm Class Analyzer), ISAS, CEROS II

• Eliminates inter-observer variability (manual analysis: CV ~20-30%; CASA: CV ~5-10%)
• Objective; reproducible
• Measures kinematic parameters not possible manually
• Higher throughput
• Better prediction of IVF outcome when combined with morphology

• Cannot replace morphology assessment (still manual with Kruger criteria)
• Cellular debris, non-sperm cells can be misidentified as sperm
• Different CASA systems have different algorithms → results not interchangeable
• Expensive; requires standardization
• Cannot assess sperm DNA integrity or function directly

• WHO 2021 reference values are based on men who achieved pregnancy within 12 months
• Semen analysis should be done on at least 2 specimens, 2-7 days apart, to account for biological variation
• Morphology: must use strict Kruger criteria; WHO 2021 recommends ≥200 sperm counted

---